NYSE:BSX - Boston Scientific Stock Price, Price Target & More

$28.84 -0.05 (-0.17 %)

(As of 04/23/2018 02:17 AM ET)

Previous Close$28.84

Today's Range$28.82 - $29.15

52-Week Range$24.54 - $29.93

Volume8.66 million shs

Average Volume7.12 million shs

Market Capitalization$39.65 billion

P/E Ratio22.89

Dividend YieldN/A

Beta0.81

About Boston Scientific (NYSE:BSX)

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy systems, wires, and stents to treat venous diseases; and peripheral embolization devices, microcatheters, and drainage catheters to treat various cancers. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to treat abnormalities; remote patient management system; implantable cardiac resynchronization therapy pacemaker systems; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, mapping system, and other accessories. Further, it provides products to diagnose and treat diseases of the gastrointestinal and pulmonary conditions; devices to diagnose, treat, and palliate pulmonary diseases within the airway and lungs; and products to treat various urological and pelvic conditions; deep brain stimulation systems for the treatment of parkinson's disease, tremor, and intractable primary and secondary dystonia; and spinal cord stimulator systems for the management of chronic pain. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.

Receive BSX News and Ratings via Email

Sign-up to receive the latest news and ratings for BSX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments

Sub-IndustryHealth Care Equipment

SectorMedical

SymbolNYSE:BSX

CUSIP10113710

Webwww.bostonscientific.com

Phone508-683-4000

Debt

Debt-to-Equity Ratio0.54%

Current Ratio0.68%

Quick Ratio0.49%

Price-To-Earnings

Trailing P/E Ratio22.89

Forward P/E Ratio21.05

P/E Growth2.09

Sales & Book Value

Annual Sales$9.05 billion

Price / Sales4.38

Cash Flow$1.8936 per share

Price / Cash15.23

Book Value$5.11 per share

Price / Book5.64

Profitability

EPS (Most Recent Fiscal Year)$1.26

Net Income$105 million

Net Margins1.15%

Return on Equity24.27%

Return on Assets9.48%

Miscellaneous

Employees29,000

Outstanding Shares1,374,910,000

How to Become a New Pot Stock Millionaire

Boston Scientific (NYSE:BSX) Frequently Asked Questions

What is Boston Scientific's stock symbol?

Boston Scientific trades on the New York Stock Exchange (NYSE) under the ticker symbol "BSX."

How were Boston Scientific's earnings last quarter?

Boston Scientific (NYSE:BSX) announced its quarterly earnings data on Thursday, February, 1st. The medical equipment provider reported $0.34 earnings per share for the quarter, hitting the consensus estimate of $0.34. The medical equipment provider earned $2.41 billion during the quarter, compared to the consensus estimate of $2.39 billion. Boston Scientific had a return on equity of 24.27% and a net margin of 1.15%. Boston Scientific's revenue for the quarter was up 9.9% on a year-over-year basis. During the same period in the prior year, the company earned $0.30 EPS. View Boston Scientific's Earnings History.

When is Boston Scientific's next earnings date?

Boston Scientific is scheduled to release their next quarterly earnings announcement on Wednesday, April, 25th 2018. View Earnings Estimates for Boston Scientific.

What guidance has Boston Scientific issued on next quarter's earnings?

Boston Scientific updated its FY18 earnings guidance on Thursday, February, 1st. The company provided earnings per share (EPS) guidance of $1.35-1.39 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.38. The company issued revenue guidance of $9.650-$9.800 billion, compared to the consensus revenue estimate of $9.60 billion.Boston Scientific also updated its Q1 guidance to $0.30-0.32 EPS.

What price target have analysts set for BSX?

19 Wall Street analysts have issued 1-year target prices for Boston Scientific's shares. Their forecasts range from $27.00 to $35.00. On average, they anticipate Boston Scientific's share price to reach $31.3684 in the next twelve months. View Analyst Ratings for Boston Scientific.

What are Wall Street analysts saying about Boston Scientific stock?

Here are some recent quotes from research analysts about Boston Scientific stock:

1. According to Zacks Investment Research, "Despite back-to-back hurricances, Boston Scientific managed to registered solid third-quarter show. An improving foreign exchange scenario has also started to contribute to the company’s overall top line performance. The raised guidance is indicative of this bullish trend to continue through the rest of 2017. The company is leaving no stone unturned to strengthen its core business and invest more in global markets. Among the recent developments, worth mentioning is the acquisition of Apama Medical, in the field of atrial fibrillation. On the flip side, Boston Scientific's unimpressive pacemaker performance within the core CRM continues remains a drag. This apart, based on the recent announcement, we believe further delay in relaunch of the earlier-recalled Lotus range of heart devices is expected to hamper sales in 2018 too. In the past three months, Boston Scientific has been trading below the broader industry." (1/30/2018)
2. Canaccord Genuity analysts commented, "We reiterate our BUY rating and $35 year-end target price on shares of BSX. Our key takeaways from our meeting last week with senior management in San Francisco (as well as incremental tidbits we gleaned over the weekend at the North American Neuromodulation Society (NANS) conference in Vegas) support our general hypothesis on the stock: We expect BSX to deliver top- and bottom-line growth rates above the large-cap medical device peer group average over the 2018-2020 timeframe." (1/17/2018)
3. Jefferies Group LLC analysts commented, "We are re-establishing estimates, a Buy rating and $14.00 PT for Flex Pharma. Flex is developing FLX-787, an innovative anti-cramp drug in amyotrophic lateral sclerosis (ALS), Charcot-Marie-Tooth disease (CMT) and multiple sclerosis (MS). We believe CMT , on which we base our PT , has the highest chance of success. We anticipate Ph2 data in 1Q’18 (MS) and 3Q’18 (ALS, CMT). In 2Q’16, Flex launched HOTSHOT , a consumer beverage for exercise- associated muscle cramps that works via the same mechanisms as FLX-787." (9/7/2017)
4. Needham & Company LLC analysts commented, "BSX beat consensus 1Q17 revenue but missed consensus EPS due to expense associated with the Lotus withdrawal. Management raised its revenue guidance but maintained its EPS guidance for 2017. BSX’s organic revenue growth slowed slightly to 9% in 1Q17 from 10% in 4Q16 despite facing a more difficult comp. MedSurg growth accelerated and offset slower Cardiovascular growth as BSX lapped the US Synergy launch. Margins were below expectations with BSX’s gross margin down 170 bps Y/Y and operating margin down 210 bps Y/Y but this was mostly due to the impact of the Lotus withdrawal." (4/27/2017)

Who are some of Boston Scientific's key competitors?

Some companies that are related to Boston Scientific include Becton Dickinson (BDX), Stryker (SYK), Fresenius (FSNUY), Baxter International (BAX), ResMed (RMD), Abiomed (ABMD), Teleflex (TFX), Dexcom (DXCM), Hill-Rom (HRC), ICU Medical (ICUI), Insulet (PODD), Globus Medical (GMED), Cantel Medical (CMD), Penumbra (PEN), Haemonetics (HAE), NuVasive (NUVA), Nevro (NVRO) and Merit Medical Systems (MMSI).

Who are Boston Scientific's key executives?

Boston Scientific's management team includes the folowing people:

Mr. Michael F. Mahoney, Chairman, Pres & CEO (Age 53)
Mr. Daniel J. Brennan, Exec. VP & CFO (Age 52)
Mr. Joseph M. Fitzgerald, Exec. VP & Pres of Rhythm Management (Age 54)
Mr. Kevin J. Ballinger, Exec. VP & Pres of Interventional Cardiology (Age 45)
Mr. Edward F. Mackey, Exec. VP of Operations (Age 55)

Has Boston Scientific been receiving favorable news coverage?

News articles about BSX stock have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Boston Scientific earned a coverage optimism score of 0.12 on Accern's scale. They also gave media headlines about the medical equipment provider an impact score of 46.59 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

How do I buy shares of Boston Scientific?

Shares of BSX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Boston Scientific's stock price today?

One share of BSX stock can currently be purchased for approximately $28.84.

How big of a company is Boston Scientific?

Boston Scientific has a market capitalization of $39.65 billion and generates $9.05 billion in revenue each year. The medical equipment provider earns $105 million in net income (profit) each year or $1.26 on an earnings per share basis. Boston Scientific employs 29,000 workers across the globe.

How can I contact Boston Scientific?

Boston Scientific's mailing address is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-683-4000 or via email at [email protected]

MarketBeat Community Rating for Boston Scientific (BSX)

Community Ranking:		2.6 out of 5 ( )
Outperform Votes:		621 (Vote Outperform)
Underperform Votes:		564 (Vote Underperform)
Total Votes:		1,185

MarketBeat's community ratings are surveys of what our community members think about Boston Scientific and other stocks. Vote "Outperform" if you believe BSX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BSX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Boston Scientific (NYSE:BSX) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

19 Wall Street analysts have issued ratings and price targets for Boston Scientific in the last 12 months. Their average twelve-month price target is $31.3684, suggesting that the stock has a possible upside of 8.77%. The high price target for BSX is $35.00 and the low price target for BSX is $27.00. There are currently 4 hold ratings, 14 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.84	2.84	2.83	2.78
Ratings Breakdown:	0 Sell Rating(s) 4 Hold Rating(s) 14 Buy Rating(s) 1 Strong Buy Rating(s)	0 Sell Rating(s) 4 Hold Rating(s) 14 Buy Rating(s) 1 Strong Buy Rating(s)	0 Sell Rating(s) 4 Hold Rating(s) 13 Buy Rating(s) 1 Strong Buy Rating(s)	0 Sell Rating(s) 4 Hold Rating(s) 14 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$31.3684	$31.0556	$30.8750	$30.9667
Price Target Upside:	8.77% upside	11.31% upside	13.30% upside	4.58% upside

Boston Scientific (NYSE:BSX) Consensus Price Target History

Price Target History for Boston Scientific (NYSE:BSX)

Boston Scientific (NYSE:BSX) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/5/2018	Bank of America	Boost Price Target	Buy -> Buy	$30.00 -> $34.00	Low
3/27/2018	Needham & Company LLC	Reiterated Rating	Buy	$35.00	High
3/19/2018	Morgan Stanley	Boost Price Target	Overweight -> Overweight	$30.00 -> $33.00	Low
3/5/2018	Royal Bank of Canada	Reiterated Rating	Top Pick	$32.00	Medium
2/23/2018	Piper Jaffray	Initiated Coverage	Overweight -> Overweight	$31.00	Medium
2/2/2018	Jefferies Group	Reiterated Rating	Hold -> Neutral		Low
1/17/2018	Canaccord Genuity	Reiterated Rating	Buy		Low
1/10/2018	Barclays	Reiterated Rating	Buy	$32.00	Low
1/3/2018	Evercore ISI	Initiated Coverage	In -> In-Line	$27.00	Medium
12/12/2017	BMO Capital Markets	Reiterated Rating	Buy	$32.00	Low
12/4/2017	SunTrust Banks	Set Price Target	Buy	$33.00	Low
11/30/2017	Cowen	Set Price Target	Buy	$31.00	Low
11/30/2017	BTIG Research	Upgrade	Neutral -> Buy	$31.00	Medium
11/29/2017	JPMorgan Chase	Reiterated Rating	Buy		Low
11/29/2017	Oppenheimer	Reiterated Rating	Hold		High
9/25/2017	Stifel Nicolaus	Reiterated Rating	Buy	$32.00	Low
8/1/2017	UBS	Reiterated Rating	Buy	$30.00 -> $31.00	Low
6/16/2017	Wells Fargo	Reiterated Rating	Outperform	$29.50 -> $31.00	Low
5/16/2017	Goldman Sachs	Initiated Coverage	Neutral -> Neutral	$28.00	Low
4/12/2017	Guggenheim	Reiterated Rating	Buy		Low
2/23/2017	Northland Securities	Reiterated Rating	Positive		N/A
10/6/2016	Citigroup	Boost Price Target	Buy	$28.00 -> $29.00	N/A
9/1/2016	Argus	Upgrade	Hold -> Buy	$23.82 -> $33.00	N/A
7/29/2016	Credit Suisse Group	Reiterated Rating	Buy		N/A
7/29/2016	Leerink Swann	Reiterated Rating	Buy		N/A
7/29/2016	Wedbush	Boost Price Target	Neutral	$23.00 -> $25.00	N/A
7/28/2016	Benchmark	Boost Price Target	Buy	$25.00 -> $31.00	N/A

(Data available from 4/23/2016 forward)

Boston Scientific (NYSE:BSX) Earnings History and Estimates Chart

Earnings by Quarter for Boston Scientific (NYSE:BSX)

Boston Scientific (NYSE:BSX) Earnings Estimates

2018 EPS Consensus Estimate: $1.37

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	4	$0.31	$0.32	$0.31
Q2 2018	4	$0.35	$0.35	$0.35
Q3 2018	5	$0.33	$0.36	$0.34
Q4 2018	4	$0.36	$0.37	$0.37

Boston Scientific (NYSE BSX) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
4/25/2018		$0.32					N/A
2/1/2018	Q4 2017	$0.34	$0.34	$2.3925 billion	$2.4080 billion	View	Listen
10/26/2017	Q3 2017	$0.31	$0.31	$2.2127 billion	$2.2220 billion	View	N/A
7/27/2017	Q2 2017	$0.31	$0.32	$2.2122 billion	$2.2570 billion	View	N/A
4/27/2017	Q1 2017	$0.30	$0.29	$2.0819 billion	$2.16 billion	View	N/A
2/2/2017	Q416	$0.29	$0.30	$2.16 billion	$2.19 billion	View	Listen
10/26/2016	Q316	$0.27	$0.27	$2.07 billion	$2.11 billion	View	Listen
7/28/2016	Q216	$0.27	$0.27	$2.05 billion	$2.13 billion	View	Listen
4/27/2016	Q116	$0.24	$0.28	$1.91 billion	$1.96 billion	View	Listen
2/4/2016	Q415	$0.25	$0.26	$2.00 billion	$1.98 billion	View	Listen
10/28/2015	Q315	$0.23	$0.24	$1.86 billion	$1.89 billion	View	Listen
7/23/2015	Q215	$0.21	$0.22	$1.83 billion	$1.84 billion	View	Listen
4/28/2015	Q115	$0.21	$0.21	$1.78 billion	$1.77 billion	View	Listen
2/4/2015	Q414	$0.21	$0.22	$1.91 billion	$1.89 billion	View	Listen
10/22/2014	Q314	$0.20	$0.20	$1.82 billion	$1.85 billion	View	Listen
7/24/2014	Q214	$0.20	$0.21	$1.87 billion	$1.87 billion	View	Listen
4/29/2014	Q114	$0.18	$0.20	$1.80 billion	$1.77 billion	View	Listen
2/4/2014	Q4	$0.13	$0.21	$1.8287 billion	$1.8380 billion	View	Listen
10/24/2013	Q313	$0.09	$0.17	$1.73 billion	$1.74 billion	View	Listen
7/25/2013	Q2 2013	$0.10	$0.18	$1.78 billion	$1.81 billion	View	Listen
4/25/2013	Q1 2013	$0.09	$0.16	$1.7881 billion	$1.7610 billion	View	Listen
1/29/2013	Q4 2012	$0.11	$0.18	$1.76 billion	$1.82 billion	View	Listen
10/18/2012		$0.11	($0.52)			View	N/A
7/26/2012		$0.08	$0.17			View	N/A
4/19/2012		$0.13	$0.15			View	N/A
2/2/2012		$0.08	$0.07			View	N/A
10/20/2011		$0.09	$0.15			View	N/A
7/28/2011		$0.08	$0.17			View	N/A
4/20/2011		$0.04	$0.01			View	N/A
2/1/2011		$0.09	$0.15			View	N/A
10/19/2010	Q3 2010	$0.06	$0.12			View	N/A
7/20/2010	Q2 2010	$0.03	$0.06			View	N/A
4/26/2010	Q1 2010	$0.08	$0.09			View	N/A
2/10/2010	Q4 2009	$0.13	$0.20			View	N/A
10/19/2009	Q3 2009	$0.14	$0.12			View	N/A
7/20/2009	Q2 2009	$0.13	$0.20			View	N/A
4/20/2009	Q1 2009	$0.12	$0.13			View	N/A
1/28/2009	Q4 2008	$0.13	$0.12			View	N/A
10/21/2008	Q3 2008	$0.11	$0.16			View	N/A
7/21/2008	Q2 2008	$0.11	$0.13			View	N/A
4/21/2008	Q1 2008	$0.12	$0.17			View	N/A
2/4/2008	Q4 2007	$0.10	$0.24			View	N/A

(Earnings results data provided by Zacks Investment Research)

Boston Scientific (NYSE:BSX) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Boston Scientific (NYSE BSX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.73%
Institutional Ownership Percentage: 91.05%

Insider Trading History for Boston Scientific (NYSE:BSX)

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Boston Scientific (NYSE BSX) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/2/2018	David A Pierce	EVP	Sell	5,000	$27.22	$136,100.00
3/20/2018	John Bradley Sorenson	SVP	Sell	2,200	$27.63	$60,786.00	34,636
3/19/2018	Daniel J Brennan	CFO	Sell	60,209	$27.87	$1,678,024.83	299,644
3/14/2018	Kevin J Ballinger	EVP	Sell	42,803	$28.32	$1,212,180.96
3/5/2018	John Bradley Sorenson	SVP	Sell	1,950	$27.43	$53,488.50
2/28/2018	David A Pierce	SVP	Sell	4,508	$27.54	$124,150.32
2/21/2018	David A Pierce	SVP	Sell	16,286	$27.00	$439,722.00
2/9/2018	Maulik Nanavaty	SVP	Sell	15,568	$25.38	$395,115.84
2/7/2018	Joseph Michael Fitzgerald	EVP	Sell	85,227	$26.48	$2,256,810.96
2/1/2018	David A Pierce	SVP	Sell	5,152	$27.43	$141,319.36	29,353
1/11/2018	David A Pierce	SVP	Sell	8,763	$27.74	$243,085.62	24,201
1/9/2018	David A Pierce	SVP	Sell	5,152	$27.00	$139,104.00	38,116
12/29/2017	Michael P Phalen	EVP	Sell	15,835	$25.25	$399,833.75
12/29/2017	Michael P. Phalen	EVP	Sell	15,835	$25.25	$399,833.75
12/1/2017	Timothy A Pratt	EVP	Sell	10,000	$26.04	$260,400.00	154,681
12/1/2017	Valley Gold Master Fund L Sun	Insider	Buy	27,431	$0.44	$12,069.64
11/29/2017	Michael P. Phalen	EVP	Sell	15,500	$26.66	$413,230.00
11/28/2017	Valley Gold Master Fund L Sun	Insider	Buy	408,006	$0.45	$183,602.70
11/1/2017	Timothy A Pratt	EVP	Sell	10,000	$28.22	$282,200.00	164,681
10/30/2017	Michael P. Phalen	EVP	Sell	15,500	$28.42	$440,510.00
10/4/2017	Supratim Bose	EVP	Sell	347,137	$29.12	$10,108,629.44
10/2/2017	Timothy A Pratt	EVP	Sell	11,061	$29.24	$323,423.64	174,681
9/29/2017	Michael P. Phalen	EVP	Sell	15,500	$28.72	$445,160.00
9/1/2017	Timothy A Pratt	EVP	Sell	10,104	$27.46	$277,455.84	185,742
8/31/2017	Maulik Nanavaty	SVP	Sell	57,031	$27.28	$1,555,805.68
8/30/2017	Maulik Nanavaty	SVP	Sell	27,031	$27.08	$731,999.48
8/29/2017	Michael P. Phalen	EVP	Sell	15,500	$26.87	$416,485.00
8/3/2017	Wendy Carruthers	SVP	Sell	12,433	$26.75	$332,582.75
8/2/2017	John Bradley Sorenson	SVP	Sell	7,900	$26.37	$208,323.00	21,680
8/1/2017	Timothy A Pratt	EVP	Sell	10,000	$26.67	$266,700.00	195,846
7/31/2017	John Bradley Sorenson	SVP	Sell	2,100	$27.15	$57,015.00	18,880
7/31/2017	Michael P. Phalen	EVP	Sell	15,500	$27.13	$420,515.00
7/11/2017	Daniel J Brennan	CFO	Sell	92,158	$27.48	$2,532,501.84	235,421
7/3/2017	Timothy A Pratt	EVP	Sell	10,000	$27.87	$278,700.00	205,846
6/29/2017	Michael P. Phalen	EVP	Sell	15,500	$28.02	$434,310.00
6/9/2017	David A Pierce	SVP	Sell	13,562	$28.00	$379,736.00	33,701
6/2/2017	David A Pierce	SVP	Sell	2,972	$27.70	$82,324.40	28,572
6/1/2017	Timothy A Pratt	EVP	Sell	10,000	$27.13	$271,300.00	215,846
5/30/2017	Michael P. Phalen	EVP	Sell	15,500	$27.25	$422,375.00
5/17/2017	Kevin J. Ballinger	EVP	Sell	28,864	$26.14	$754,504.96
5/1/2017	Timothy A Pratt	EVP	Sell	10,000	$26.37	$263,700.00	225,846
4/26/2017	David A Pierce	SVP	Sell	10,250	$26.00	$266,500.00	35,850
4/26/2017	Michael P. Phalen	EVP	Sell	34,773	$26.00	$904,098.00
4/10/2017	John Bradley Sorenson	SVP	Sell	2,950	$24.66	$72,747.00	20,980
4/3/2017	Timothy A Pratt	EVP	Sell	10,000	$24.87	$248,700.00	235,846
3/29/2017	Michael P. Phalen	EVP	Sell	79,045	$24.55	$1,940,554.75
3/3/2017	David A Pierce	SVP	Sell	25,012	$25.01	$625,550.12	25,600
3/3/2017	Timothy A Pratt	EVP	Sell	23,540	$25.01	$588,735.40	245,846
2/27/2017	David A Pierce	SVP	Sell	3,417	$24.84	$84,878.28	34,267
2/27/2017	Timothy A Pratt	EVP	Sell	4,832	$24.84	$120,026.88	248,758
2/7/2017	Keith D Dawkins	EVP	Sell	80,783	$25.21	$2,036,539.43	75,864
1/9/2017	David A Pierce	SVP	Sell	10,232	$22.24	$227,559.68	25,600
1/9/2017	Timothy A Pratt	EVP	Sell	6,195	$22.24	$137,776.80	231,273
12/1/2016	Timothy A Pratt	EVP	Sell	26,726	$20.48	$547,348.48	260,430
8/11/2016	John Bradley Sorenson	SVP	Sell	2,500	$23.90	$59,750.00	12,615
8/1/2016	Michael F Mahoney	CEO	Sell	44,400	$24.44	$1,085,136.00	1,388,177
8/1/2016	Timothy A Pratt	EVP	Sell	24,000	$24.46	$587,040.00	287,495
7/20/2016	David A Pierce	SVP	Sell	2,480	$24.03	$59,594.40	28,080
7/20/2016	Michael P. Phalen	EVP	Sell	35,000	$24.03	$841,050.00
6/1/2016	Michael F Mahoney	CEO	Sell	100,000	$22.69	$2,269,000.00	1,532,577
6/1/2016	Timothy A Pratt	EVP	Sell	24,229	$22.66	$549,029.14	301,724
5/11/2016	John Bradley Sorenson	SVP	Sell	2,800	$22.15	$62,020.00	15,115
5/10/2016	Keith D Dawkins	EVP	Sell	80,000	$22.15	$1,772,000.00	150,227
5/6/2016	Jeffrey B Mirviss	SVP	Sell	24,659	$21.94	$541,018.46	71,975
5/3/2016	Joseph Michael Fitzgerald	EVP	Sell	79,960	$21.81	$1,743,927.60	92,020
5/2/2016	Michael F Mahoney	CEO	Sell	100,000	$22.12	$2,212,000.00	1,632,577
5/2/2016	Timothy A Pratt	EVP	Sell	24,000	$21.93	$526,320.00	308,724
4/27/2016	Kevin J Ballinger	SVP	Sell	111,807	$21.62	$2,417,267.34	83,600
4/27/2016	Timothy A Pratt	EVP	Sell	39,927	$21.40	$854,437.80	291,724
4/4/2016	Jeffrey B Mirviss	SVP	Sell	18,422	$19.00	$350,018.00	96,634
4/1/2016	Michael F Mahoney	CEO	Sell	100,000	$18.90	$1,890,000.00	1,732,577
4/1/2016	Timothy A Pratt	EVP	Sell	24,000	$18.73	$449,520.00	355,651
3/11/2016	Kevin J Ballinger	SVP	Sell	16,705	$18.00	$300,690.00	46,970
3/8/2016	Karen Prange	SVP	Sell	14,747	$17.27	$254,680.69	38,395
3/2/2016	Michael P. Phalen	EVP	Sell	10,665	$17.17	$183,118.05	89,309
3/1/2016	Michael F Mahoney	CEO	Sell	100,000	$16.96	$1,696,000.00	1,832,577
3/1/2016	Timothy A Pratt	EVP	Sell	15,068	$16.97	$255,703.96	338,651
2/29/2016	Kevin J. Ballinger	SVP	Sell	2,114	$17.17	$36,297.38
2/29/2016	Michael P. Phalen	EVP	Sell	1,819	$17.19	$31,268.61
2/25/2016	Daniel J Brennan	CFO	Sell	103,211	$17.22	$1,777,293.42	202,659
2/25/2016	Kevin J. Ballinger	SVP	Sell	1,903	$17.48	$33,264.44
2/25/2016	Michael P. Phalen	EVP	Sell	34,106	$17.28	$589,351.68
2/17/2016	Kevin J. Ballinger	SVP	Sell	7,616	$17.37	$132,289.92
2/12/2016	Charles J Dockendorff	Director	Buy	30,000	$16.49	$494,700.00	41,598
2/8/2016	Karen Prange	SVP	Sell	6,216	$16.05	$99,766.80	23,647
1/8/2016	Timothy A Pratt	EVP	Sell	7,160	$17.67	$126,517.20	303,776
1/7/2016	Kevin J Ballinger	SVP	Sell	19,059	$17.73	$337,916.07	30,323
1/5/2016	Jeffrey B Mirviss	SVP	Sell	9,953	$18.00	$179,154.00	82,535
12/1/2015	Timothy A. Pratt	EVP	Sell	24,000	$18.43	$442,320.00	282,295
11/16/2015	Ernest Mario	Director	Sell	125,000	$17.63	$2,203,750.00	86,032
11/9/2015	John Bradley Sorenson	SVP	Sell	4,469	$18.68	$83,480.92	5,605
11/9/2015	Joseph Michael Fitzgerald	EVP	Sell	26,220	$18.58	$487,167.60	103,925
11/5/2015	Timothy A Pratt	EVP	Sell	19,598	$19.00	$372,362.00	289,295
10/28/2015	Jeffrey B Mirviss	SVP	Sell	9,492	$18.00	$170,856.00	81,262
10/28/2015	Timothy A Pratt	EVP	Sell	3,500	$18.00	$63,000.00	315,893
10/5/2015	Timothy A Pratt	EVP	Sell	3,500	$17.34	$60,690.00	319,393
10/1/2015	Timothy A. Pratt	EVP	Sell	17,000	$16.33	$277,610.00	322,893
8/21/2015	John E Abele	Director	Buy	200,000	$16.77	$3,354,000.00	92,983
8/19/2015	John E Abele	Director	Buy	200,000	$17.48	$3,496,000.00	92,983
8/17/2015	John E Abele	Director	Buy	100,000	$17.50	$1,750,000.00
7/7/2015	Karen Prange	SVP	Sell	17,456	$17.66	$308,272.96
5/29/2015	Maulik Nanavaty	SVP	Sell	71,558	$18.52	$1,325,254.16
5/28/2015	Wendy Carruthers	SVP	Sell	42,281	$17.91	$757,252.71
5/18/2015	Ernest Mario	Director	Sell	50,000	$18.09	$904,500.00
5/14/2015	John E Sununu	Director	Sell	10,000	$17.87	$178,700.00
5/11/2015	John Bradley Sorenson	SVP	Sell	8,735	$17.49	$152,775.15
3/20/2015	David A Pierce	SVP	Sell	18,050	$18.00	$324,900.00
3/20/2015	Michael P Phalen	EVP	Sell	46,085	$17.94	$826,764.90
3/16/2015	Michael P Phalen	EVP	Sell	30,022	$17.18	$515,777.96
3/13/2015	John Bradley Sorenson	SVP	Sell	3,830	$16.84	$64,497.20
3/9/2015	David A Pierce	SVP	Sell	2,561	$16.54	$42,358.94
3/3/2015	David A Pierce	SVP	Sell	8,983	$16.79	$150,824.57
3/3/2015	Michael P Phalen	EVP	Sell	12,768	$16.79	$214,374.72
2/27/2015	David A Pierce	SVP	Sell	19,046	$16.80	$319,972.80
2/27/2015	Michael P Phalen	EVP	Sell	1,819	$16.80	$30,559.20
2/19/2015	David A Pierce	SVP	Sell	11,958	$16.46	$196,828.68
2/19/2015	Michael P Phalen	EVP	Sell	13,188	$16.44	$216,810.72
2/10/2015	Joseph Michael Fitzgerald	EVP	Sell	61,208	$14.66	$897,309.28
2/9/2015	David A Pierce	SVP	Sell	5,000	$14.66	$73,300.00
2/6/2015	Kevin J Ballinger	SVP	Sell	21,408	$15.06	$322,404.48
1/20/2015	Michael P Phalen	EVP	Sell	10,000	$14.54	$145,400.00
1/8/2015	David A Pierce	SVP	Sell	18,612	$14.31	$266,337.72
1/8/2015	Michael P Phalen	EVP	Sell	27,589	$14.31	$394,798.59
1/5/2015	Michael P Phalen	EVP	Sell	10,000	$13.75	$137,500.00
12/10/2014	Karen Prange	SVP	Sell	19,753	$12.64	$249,677.92
12/8/2014	David A Pierce	SVP	Sell	5,000	$12.90	$64,500.00
12/1/2014	Ernest Mario	Director	Sell	10,000	$12.96	$129,600.00
11/28/2014	Michael F Mahoney	CEO	Buy	11,700	$12.89	$150,813.00
11/10/2014	Edward J Ludwig	Director	Buy	10,000	$13.38	$133,800.00
11/5/2014	John E Sununu	Director	Sell	8,997	$13.38	$120,379.86
11/3/2014	Ernest Mario	Director	Sell	10,000	$13.30	$133,000.00
10/8/2014	Ernest Mario	Director	Sell	10,000	$12.06	$120,600.00
9/2/2014	Ernest Mario	Director	Sell	10,000	$12.60	$126,000.00
8/15/2014	Michael P Phalen	EVP	Sell	11,471	$12.58	$144,305.18
8/1/2014	Ernest Mario	Director	Sell	10,000	$12.58	$125,800.00
7/30/2014	David A Pierce	SVP	Sell	157	$12.97	$2,036.29
7/15/2014	Michael P Phalen	EVP	Sell	67,500	$13.04	$880,200.00
7/1/2014	Ernest Mario	Director	Sell	10,000	$12.95	$129,500.00
6/16/2014	Michael P Phalen	EVP	Sell	13,500	$13.02	$175,770.00
6/2/2014	Ernest Mario	Director	Sell	10,000	$12.88	$128,800.00
5/15/2014	Michael Phalen	EVP	Sell	13,500	$12.76	$172,260.00	127,486
5/1/2014	Ernest Mario	Director	Sell	10,000	$12.58	$125,800.00	317,855
4/15/2014	Michael Phalen	EVP	Sell	13,500	$13.25	$178,875.00	127,486
4/1/2014	Ernest Mario	Director	Sell	10,000	$13.55	$135,500.00	327,855
3/17/2014	Michael Phalen	EVP	Sell	13,500	$13.05	$176,175.00	127,486
3/6/2014	David Pierce	SVP	Sell	5,316	$13.44	$71,447.04	43,161
3/6/2014	Michael Phalen	EVP	Sell	7,281	$13.44	$97,856.64	127,486
2/27/2014	David Pierce	SVP	Sell	2,057	$13.29	$27,337.53	47,990
2/27/2014	Michael Phalen	EVP	Sell	3,166	$13.29	$42,076.14	130,848
2/21/2014	David Pierce	SVP	Sell	3,199	$13.22	$42,290.78	25,600
2/21/2014	Michael Phalen	EVP	Sell	3,222	$13.22	$42,594.84	84,300
2/18/2014	Michael Phalen	EVP	Sell	13,500	$13.30	$179,550.00	87,522
2/13/2014	Kristina Johnson	Director	Sell	18,000	$13.01	$234,180.00	3,124
2/6/2014	Ernest Mario	Director	Sell	17,104	$12.80	$218,931.20	347,855
2/3/2014	Ernest Mario	Director	Sell	10,000	$13.19	$131,900.00	364,959
1/6/2014	Ernest Mario	Director	Sell	10,000	$12.50	$125,000.00	374,959
12/26/2013	Ernest Mario	Director	Sell	10,000	$12.06	$120,600.00	384,959
11/26/2013	Jeffrey Capello	CFO	Sell	85,106	$11.82	$1,005,952.92	109,042
11/11/2013	Jeffrey Mirviss	SVP	Sell	26,000	$11.91	$309,660.00	39,190
8/29/2013	Jeffrey Capello	CFO	Sell	525,000	$10.68	$5,607,000.00	147,447
8/16/2013	Joseph Michael Fitzgerald	SVP	Sell	9,202	$11.02	$101,406.04	93,191
8/14/2013	Kevin Ballinger	SVP	Sell	38,171	$11.28	$430,568.88	73,519
5/31/2013	Jeffrey B Mirviss	SVP	Sell	10,941	$9.37	$102,517.17
5/30/2013	Wendy Carruthers	SVP	Sell	25,001	$9.16	$229,009.16
5/29/2013	Nelda J Connors	Director	Sell	24,116	$9.17	$221,143.72
5/6/2013	Ernest Mario	Director	Buy	30,000	$7.76	$232,800.00
11/13/2012	Nj Nicholas Jr	Director	Buy	20,000	$5.28	$105,600.00
11/9/2012	Nj Nicholas Jr	Director	Buy	25,000	$5.17	$129,250.00
8/6/2012	Ernest Mario	Director	Buy	32,000	$5.29	$169,280.00

(Data available from 1/1/2013 forward)

Boston Scientific (NYSE BSX) News Headlines

Source:

Date	Headline
	Boston Scientific (BSX) Expected to Post Quarterly Sales of $2.34 Billion www.americanbankingnews.com - April 21 at 2:32 AM
	Boston Scientific (BSX) Earns Buy Rating from BMO Capital Markets www.americanbankingnews.com - April 20 at 6:54 PM
	$0.31 EPS Expected for Boston Scientific (BSX) This Quarter www.americanbankingnews.com - April 19 at 7:21 PM
	Boston Scientific (BSX) Downgraded by Zacks Investment Research to "Sell" www.americanbankingnews.com - April 19 at 11:46 AM
	Boston Scientific (BSX) Given "Buy" Rating at Royal Bank of Canada www.americanbankingnews.com - April 19 at 12:28 AM
	Boston Scientific buys Harker School grad's med-tech business for $275M www.bizjournals.com - April 18 at 10:39 AM
	Boston Scientific (BSX) Scheduled to Post Quarterly Earnings on Wednesday www.americanbankingnews.com - April 18 at 2:46 AM
	Boston Scientific (BSX) Receives Outperform Rating from Cowen www.americanbankingnews.com - April 17 at 11:28 PM
	Can MedSurg Business Aid Boston Scientific (BSX) Q1 Earnings? www.zacks.com - April 17 at 10:45 AM
	Boston Scientific Prevails In European Patent Dispute With Edwards Lifesciences finance.yahoo.com - April 17 at 10:45 AM
	Boston Scientific buys nVision Medical for $275 million finance.yahoo.com - April 17 at 10:45 AM
	How Profiteers Lure Women Into Often-Unneeded Surgery www.nytimes.com - April 16 at 3:43 PM
	BRIEF-Boston Scientific Announces Acquisition Of NVision Medical Corp www.reuters.com - April 16 at 3:43 PM
	Boston Scientific (BSX) Downgraded by BidaskClub to "Hold" www.americanbankingnews.com - April 16 at 11:39 AM
	Boston Scientific acquires nVision Medical for up to $275M seekingalpha.com - April 16 at 10:27 AM
	Boston Scientific Acquires NVision Medical In Up To $275 Mln Deal - Quick Facts www.nasdaq.com - April 16 at 10:27 AM
	Boston Scientific Announces Acquisition Of nVision Medical Corporation finance.yahoo.com - April 16 at 10:27 AM
	A 32-Year-Old's Startup, Inspired By A Health Scare, Sells For $275 Million finance.yahoo.com - April 16 at 10:27 AM
	Boston Scientific (BSX) Rating Reiterated by Cowen www.americanbankingnews.com - April 15 at 9:31 AM
	Boston Scientific (BSX) Upgraded by Zacks Investment Research to "Hold" www.americanbankingnews.com - April 15 at 8:37 AM
	Boston Scientific (BSX) Cut to "Sell" at BidaskClub www.americanbankingnews.com - April 14 at 6:22 PM
	WATCHMAN to Aid Boston Scientific (BSX) Q1 Earnings Amid Woes finance.yahoo.com - April 12 at 11:34 AM
	MitraClip Drives Growth, Gets Reimbursement Approval in Japan finance.yahoo.com - April 9 at 3:37 PM
	SunTrust Banks Reaffirms "Buy" Rating for Boston Scientific (BSX) www.americanbankingnews.com - April 8 at 4:51 PM
	Needham & Company LLC Reiterates Buy Rating for Boston Scientific (BSX) www.americanbankingnews.com - April 8 at 11:05 AM
	Boston Scientific (BSX) PT Raised to $34 at BofA/Merrill Lynch www.streetinsider.com - April 7 at 1:56 PM
	Boston Scientific (BSX) Earns Buy Rating from Analysts at Canaccord Genuity www.americanbankingnews.com - April 5 at 9:36 PM
	Boston Scientific (BSX) Price Target Increased to $34.00 by Analysts at Bank of America www.americanbankingnews.com - April 5 at 1:11 PM
	What’s behind Edwards Lifesciences’ Stock Rise? finance.yahoo.com - April 4 at 2:28 PM
	Boston Scientific to Acquire Securus Medical, Boost EP Unit finance.yahoo.com - April 4 at 2:28 PM
	Edwards Lifesciences and Boston Scientific: Patent Dispute Update finance.yahoo.com - April 4 at 2:28 PM
	Boston Scientific Announces Acquisition of Securus Medical finance.yahoo.com - April 4 at 2:28 PM
	Wall Street’s Recommendations for BSX Stock finance.yahoo.com - April 4 at 2:28 PM
	Boston Scientific (BSX) Downgraded by Zacks Investment Research to "Hold" www.americanbankingnews.com - April 4 at 1:21 PM
	Boston Scientific Co. (BSX) Receives Average Rating of "Buy" from Analysts www.americanbankingnews.com - April 4 at 11:51 AM
	Zacks: Brokerages Anticipate Boston Scientific Co. (BSX) Will Announce Quarterly Sales of $2.34 Billion www.americanbankingnews.com - April 4 at 2:14 AM
	David A. Pierce Sells 5,000 Shares of Boston Scientific Co. (BSX) Stock www.americanbankingnews.com - April 3 at 10:31 PM
	Boston Scientific (BSX) Rating Lowered to Hold at ValuEngine www.americanbankingnews.com - April 3 at 6:26 PM
	Boston Scientific (BSX) Buys Securus Medical Group for $40 Million Up-Front and $10 Million Contingent www.streetinsider.com - April 3 at 10:57 AM
	Brokerages Expect Boston Scientific Co. (BSX) to Post $0.31 EPS www.americanbankingnews.com - April 2 at 7:10 PM
	Boston Scientific (BSX) Given Buy Rating at Royal Bank of Canada www.americanbankingnews.com - April 1 at 6:28 PM
	Boston Scientific (BSX) Coverage Initiated by Analysts at Evercore ISI www.americanbankingnews.com - March 30 at 11:40 PM
	More Controversy Over Major Cardiology Clinical Trial finance.yahoo.com - March 30 at 3:34 PM
	Boston Scientific (BSX) Stock Rating Lowered by Zacks Investment Research www.americanbankingnews.com - March 29 at 9:36 PM
	These medical devices are getting better at treating chronic pain finance.yahoo.com - March 29 at 11:04 AM
	Baxter International Created a New Reporting Structure for 2018 finance.yahoo.com - March 28 at 3:33 PM
	Boston Scientific's (BSX) "Buy" Rating Reiterated at Needham & Company LLC www.americanbankingnews.com - March 28 at 12:58 PM
	How Do Analysts See Boston Scientific Corporation (NYSE:BSX) Performing Over The Next Few Years? finance.yahoo.com - March 28 at 10:39 AM
	Boston Scientific Prevails In U.K. Edwards Lifesciences Litigation www.prnewswire.com - March 28 at 5:58 AM
	Boston Scientific cuts nearly 300 workers at Los Angeles facility www.bizjournals.com - March 27 at 3:43 PM

Boston Scientific (NYSE:BSX) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Boston Scientific (NYSE:BSX) Income Statement, Balance Sheet and Cash Flow Statement

Boston Scientific (NYSE BSX) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff